The online version of this article (doi:10.1186/1475-2840-11-25) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
CdE and PSK researched the data, performed the statistical analyses and wrote the manuscript. KJG, MvdD, PLS and GER contributed to the discussion. All authors were involved in the design of the study and read and approved the final manuscript.
People with central obesity have an increased risk for developing the metabolic syndrome, type 2 diabetes and cardiovascular disease. However, a substantial part of obese individuals have no other cardiovascular risk factors, besides their obesity. High sensitivity C-reactive protein (hs-CRP), a marker of systemic inflammation and a predictor of type 2 diabetes and cardiovascular disease, is associated with the metabolic syndrome and its separate components. We evaluated the use of hs-CRP to discriminate between centrally obese people with and without the metabolic syndrome.
1165 people with central obesity but without any previous diagnosis of hypertension, dyslipidemia, diabetes or cardiovascular disease, aged 20-70 years, underwent a physical examination and laboratory assays to determine the presence of the metabolic syndrome (NCEP ATP III criteria). Multivariable linear regression analyses were performed to assess which metabolic syndrome components were independently associated with hs-CRP. A ROC curve was drawn and the area under the curve was calculated to evaluate whether hs-CRP was capable to predict the presence of the metabolic syndrome.
Median hs-CRP levels were significantly higher in individuals with central obesity with the metabolic syndrome (n = 417; 35.8%) compared to individuals with central obesity without the metabolic syndrome (2.2 mg/L (IQR 1.2-4.0) versus 1.7 mg/L (IQR 1.0-3.4); p < 0.001). Median hs-CRP levels increased with an increasing number of metabolic syndrome components present. In multivariable linear regression analyses, waist circumference and triglycerides were the only components that were independently associated with hs-CRP after adjusting for smoking, gender, alcohol consumption and the other metabolic syndrome components. The area under the ROC curve was 0.57 (95%-CI 0.53-0.60).
Hs-CRP has limited capacity to predict the presence of the metabolic syndrome in a population with central obesity.
Authors’ original file for figure 112933_2012_460_MOESM1_ESM.jpeg
Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, Forouhi NG, Freeman DJ, Jukema JW, Lennon L, Macfarlane PW, Murphy MB, Packard CJ, Stott DJ, Westendorp RG, Whincup PH, Shepherd J, Wannamethee SG: Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008, 371: 1927-1935. 10.1016/S0140-6736(08)60602-9. CrossRefPubMed
Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002, 51: 1596-1600. 10.2337/diabetes.51.5.1596. CrossRefPubMed
Ilanne-Parikka P, Eriksson JG, Lindstrom J, Peltonen M, Aunola S, Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M, Valle TT, Lahtela J, Uusitupa M, Tuomilehto J: Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care. 2008, 31: 805-807. 10.2337/dc07-1117. CrossRefPubMed
Pataky Z, Bobbioni-Harsch E, Golay A: Open questions about metabolically normal obesity. Int J Obes (Lond). 2010, 34 (Suppl 2): S18-S23. CrossRef
Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR: The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008, 168: 1617-1624. 10.1001/archinte.168.15.1617. CrossRefPubMed
Kemper HGC, Ooijendijk WTM, Stiggelbout M: Consensus over de Nederlandse Norm voor Gezond Bewegen. Tijdschrift voor Sociale Gezondheidszorg. 2000, 78: 180-183.
Stalman WA, Scheltens T, Burgers JS, Hukkelhoven CW, Smorenburg SM, Banga JD, Dippel DW: NHG-Standaard Cardiovasculair risicomanagement. 2006, Houten: Bohn Stafleu van Loghum
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 1640-1645. 10.1161/CIRCULATIONAHA.109.192644. CrossRefPubMed
Taubert K, Tracy RP, Vinicor F, Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003, 107: 499-511. 10.1161/01.CIR.0000052939.59093.45. CrossRefPubMed
Macy EM, Hayes TE, Tracy RP: Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997, 43: 52-58. PubMed
Santos AC, Lopes C, Guimaraes JT, Barros H: Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes (Lond). 2005, 29: 1452-1456. 10.1038/sj.ijo.0803035. CrossRef
Zuliani G, Volpato S, Galvani M, Ble A, Bandinelli S, Corsi AM, Lauretani F, Maggio M, Guralnik JM, Fellin R, Ferrucci L: Elevated C-reactive protein levels and metabolic syndrome in the elderly: The role of central obesity data from the InChianti study. Atherosclerosis. 2009, 203: 626-632. 10.1016/j.atherosclerosis.2008.07.038. PubMedCentralCrossRefPubMed
Kressel G, Trunz B, Bub A, Hulsmann O, Wolters M, Lichtinghagen R, Stichtenoth DO, Hahn A: Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk. Atherosclerosis. 2009, 202: 263-271. 10.1016/j.atherosclerosis.2008.04.012. CrossRefPubMed
Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, Abe M, Katoh T, Ohtsuka N: High-sensitivity C-reactive protein and gamma-glutamyl transferase levels are synergistically associated with metabolic syndrome in community-dwelling persons. Cardiovasc Diabetol. 2010, 9: 87-10.1186/1475-2840-9-87. PubMedCentralCrossRefPubMed
Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003, 107: 671-674. 10.1161/01.CIR.0000055188.83694.B3. CrossRefPubMed
Faucher G, Guenard F, Bouchard L, Garneau V, Turcot V, Houde A, Tchernof A, Bergeron J, Deshaies Y, Hould FS, Lebel S, Marceau P, Vohl MC: Genetic contribution to C-reactive protein levels in severe obesity. Mol Genet Metab. 2011, 10.1016/j.ymgme.2011.11.198.
- High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis
Corine den Engelsen
Paula S Koekkoek
Kees J Gorter
Maureen van den Donk
Philippe L Salomé
Guy E Rutten
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II